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Abstract
Thyroid cancer (TC) coexisting with Hashimoto’s thyroiditis (HT) presents with several characteristic features including
multifocality and lower clinical stages compared to de novo carcinomas but its exact biology is still not understood. We
reexamined clinico-pathological and molecular correlations between Hashimoto’s thyroditis and papillary thyroid cancer. A total
of 262 patients with TC was evaluated who underwent thyroidectomy at the Surgical Department of the University of Debrecen.
Clinical data, histology and molecular data were evaluated. Our cohort included 43 patients (16.4%) with (5male, 38 female) and
219 (83.6%) patients without coexisting HT (48 male, 171 female). Hashimoto’s thyroiditis related thyroid cancer presented
predominantly (93.0% of the cases) with the papillary histological type. Multifocality was observed more frequently with
coexisting HT (16/40; 40.0%) compared to cases uninvolved (45/190; 23.7%)(p = 0.034). In contrast, lymphatic metastasis
(pN1) with a significantly reduced frequency in patients with HT (4/11; 36.4%) then without HT (34/41 pN1; 82.9%)(p =
0.002). BRAF V600E mutation could be demonstrated at significantly lower rates in cases of PTC + HT (32.1 vs 60.7%,
p < 0.005). High incidence, multifocality and papillary morphology strongly support a causal relation between TC and
preexisting Hashimoto’s thyroiditis, the latter to be considered as a preneoplastic condition promoting thyroid carcinogenesis.
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Abbreviations
ATC anaplastic thyroid carcinoma
UD CC University of Debrecen Clinical Centre
HT Hashimoto’s thyreoiditis
FTC follicular thyroid carcinoma
MF multifocal
MTC medullary thyroid carcinoma
PTC papillary thyroid carcinoma
TSH thyroid stimulating hormone
UF unifocal
Introduction
Hashimoto’s thyreoiditis (HT) is a frequent organ specific
autoimmune disease affecting the thyroid gland, leading to
the destruction of the glandular parenchyma and thyroid
hypofunction with decreased T3 and T4 levels and subsequent
elevation of TSH. The clinical diagnosis of HT is based on
functional tests and the demonstration of specific autoanti-
bodies. However, the consequences of the hyperergic immu-
nological process representing parenchymal damage and lym-
phatic infiltrate is clearly represented in histological samples
following surgery [1–3].
Thyroid cancer is one of the most common neoplasias of the
endocrine system [4]. The vast majority (87.9%) takes the form
of papillary thyroid carcinoma (PTC) [5], less frequently fol-
licular (FTC), medullary (MTC) and anaplastic carcinomas
(ATC) may occur. The diagnosis of the PTC is based on the
histopathological examination of the thyroid mass detected by
radiological imaging and aspiration cytology. In a significant
portion of cases PTC develops in multiple areas of the thyroid
parenchyma simultaneously, directing to a common etiological
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background. However, the only evidence-based etiologic fac-
tor in the pathogenesis of thyroid cancer to date is ionizing
radiation [6–8] which only rarely occurs in the patient history.
Further etiological correlations has been continously
discussed. As such, earlier studies found that PTC is more
common among patients who suffered from autoimmune lym-
phocytic thyroiditis [9–12], while others debated these findings
[13–15]. The association between the two diseases was also
supported by some more recent cross-sectional studies
[16–29]. This potential relationship is generally explained by
the misconducted follicular epithelial regeneration following
chronic inflammatory damage, however, the molecular
pathomechanism remains unclear. Cancer multifocality was
also repeatedly presented in association with HT, providing a
further basis for the causal relation between the two disorders
[16, 17, 23, 30].
Molecular genetic analyses revealed several frequent DNA
anomalies in thyroid cancer, including the mutations of BRAF
[31], NRAS [32] and RET/PTC [33] genes, the prognostic
significance of which is still debated in the individual
subcategories of thyroid carcinoma [34]. The frequency
of the BRAF mutation V600E was reported to be controver-
sial in association with multiple cancer foci and HT involve-
ment [35].
The aim of our current research was to examine the fre-
quency and the clinico-pathological characteristics in the
cases of coexisting TC and HT. We specifically focused on
currently available factors associated with thyroid carcinogen-
esis, including histology, tumor multifocality and further, the
prominent performers of theMAP kinase pathway, BRAF and
NRAS mutational status.
Materials and Methods
We re-examined the histological samples of patients whowere
operated due to thyroid disease at the Department of Surgery,
University of Debrecen between 2007 and 2012. All cases
with the final diagnosis of malignant thyroid disease were
selected from the clinical database. Non-epithelial thyroid
neoplasias were excluded from the further evaluation. The
original histological samples with representative thyroid tissue
were collected for systemic review of the thyroid cancer and
the potential involvement by HT. The study population was
thus formed by 262 samples with thyroid carcinoma.
Histological revision was made by an uniform evalu-
ation scheme. The histological diagnosis of HT was
stated if chronic lymphocytic infiltration, secondary lymphatic
follicules and follicular atrophy could be recognized. These
findings were occasionally extended by the additional pres-
ence of Hürthle cell metaplasia. The diagnosis of PTC was
confirmed when the classical histological criteria were provid-
ed: characteristic cytoarchitecture, psammoma-bodies,
nuclear abnormalities (enlarged nulcei, overlapping of nuclei,
nuclear clearing, irregular nuclear membrane, nuclear
grooves, pseudoinclusisons). In addition to the conventional
H&E staining, immunohistochemistry was performed to de-
tect the tissue antigens HBME1, galectin-3, CD56 and CK19
to support the identification of the PTC cell groups. The mul-
tifocal nature of the thyroid cancer has been stated when more
than one foci were found in a distance of over 5 mmduring the
review of the complete surgical material. Individual foci were
evaluated separately.
BRAF V600E mutation data were available in 185 cases
demonstrated from the individual tumor foci selected by his-
tology. DNAwas extracted from unstained FFPE tissue mate-
rial following macrodissection. PCR amplification and direct
sequencing of BRAF exon 15 as well as NRAS exons 2, 3 and
4 was performed by the routine procedure of our Molecular
Diagnostic Laboratory at the Department of Pathology,
University of Debrecen. Sequencing was done using the
ABI 310 genetic analyzer and Big Dye chemistry (Applied
Biosystems, Foster City, CA, USA). In parallel, immunohis-
tochemistry with the VE1 antibody (Roche Diagnostics,
Mannheim, Germany) was applied in a routine session apply-
ing the Ventana Benchmark (Roche Diagnostics) immunohis-
tochemistry station to demonstrate mutant BRAF protein in
thyroid cancer cells in tissue sections.
The histological and clinicopathological data were statisti-
cally evaluated using t-test for the mean age, chi-square test
for the male/female ratio, multifocality, lymph node involve-
ment and lymph node dissection. The tumor and TNM stage
were compared byMann-Whitney test. BRAFmutation status
in the selected case groups was compared by chi-square and
Fischer-tests using the GraphPad Prism 6.04 Trial software
(GraphPad Software, Inc. La Jolla, CA, USA).
Results
Patients and Basic Histology
Among the 262 thyroid carcinoma samples analyzed we
found 43 cases (16.4%) with clear histological signs of HT
involvement. The gender distribution showed a female pre-
dominance (38 female patients out of 43, 88.4%). The histo-
logical type of the thyroid carcinoma proved to be PTC in the
majority of the cases (40 out of 43, 93.0%), the remaining 3
cases were FTCs (7.0%). In contrast, the male vs. female ratio
was 48 vs. 171 in the 219 carcinoma patients without HT
(78.1% female dominance). Within the latter group the histol-
ogy resulted PTC in 190 cases (86.7%), FTC in 15 (6.9%),
medullary carcinoma in 12 cases (5.5%) and anaplastic carci-
noma in 2 cases (0.9%) (Table 1).
Among PTC patients the proportion of the female gender
was significantly higher in case of coexisting HT (36/40;
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90.0%), than without HT (164/190; 76.8%)(p = 0.046). In the
small group of FTC, the involvement of females also
dominated: 2/3 (66.6%) FTCs with and all FTCs (15/
15, 100%) without HT were female patients (p = 0.021).
The mean age of PTC and FTC patients was somewhat
lower for tumors with HT, than without, but these differences
were not significant.
Thyroid Cancer Multifocality and HT
The occurance of multiple cancer foci within the same resec-
tion specimen was also found to be significantly influenced by
the presence of HT (Table 2). Multifocality of PTC was sig-
nificantly more frequent with coexisting HT (16/40; 40.0%)
compared to cases uninvolved (45/190; 23.7%)(p = 0.034).
Multifocality of FTC, however, did not correlate with the
presence of HT as none of the FTC patients with HT showed
mutifocal tumor (0/3; 0%), while a minor group of patients
without HT did (4/15; 26.7%)(p = 0.196).
Tumor Stage
We also stated several differences regarding the clinical pre-
sentation of the thyroid cancer in patients suffering from HT
(Table 2). Among patients affected by both PTC and HT si-
multaneously the tumor stage (pT) was only minimally lower
(average = 1.33 ± 0.73 SD), than in patients affected by PTC
only (1.48 ± 0.76) (p = 0.065, not significant). Simillarly, we
found no clear connection between pT tumor stage in FTC
patients with or without HT. On the other hand, the pN status
proved to be different. Surgical dissection of cervical lymph
nodes was done in only 11/40 cases (27.5%) suffering from
PTC and HT simultanously and in 41/190 cases (21.6%) in
patients having PTC alone. The statistical revision confirmed,
that in case of PTC, the nodal stage (pN) was significantly
lower in the presence of HT (4/11 pN1; 34.6%) then the pa-
tients without HT (34/41 pN1; 82.9%)(p = 0.002). In patients
with FTC and HT, cervical lymph node dissection was per-
formed only in one out of the 3 cases, and in FTC patients
without HT in 1/15 cases, not allowing further comparisons.
BRAF and NRAS Mutational Status and HT
BRAF exon 15 V600 mutation analysis was performed in 185
thyroid carcinomas out of which mutations were detected in
89 cases (48.1%). No sequence variants further to the
classical V600E mutation could be demonstrated follow-
ing classical Sanger sequencing of the region. BRAF
mutation was present in a significantly higher proportion of
PTCs (88/158, 55.7%) than in the rest of cases presenting with
other histomorphology (1/27, 3.7%) (Table 3). Within the
PTC group, the classical papillary morphology was more fre-
quently involved by the V600E mutation than the follicular
variant (70/108, 64.8% vs 15/40, 36.6%, p = 0.0045).
Table 1 Clinicopathological
distribution of thyroid carcinomas
with or without Hashimoto’s
thyroiditis evaluated in the study
(n = 262)
HT + thyroid cancer Thyroid cancer without HT p
Gender distribution
• All pts
- Male/ all pts. (%) 5/43 (11.6%) 48/219 (21.9%)
- Female/ all pts. (%) 38/43 (88.4%) 171/219 (78.1%) ns
• PTC pts
- Male/ all PTC pts. (%) 4/40 (10.0%) 26/190 (23,2%)
- Female/ all PTC pts. (%) 36/40 (90.0%) 164/190 (76.8%) 0.046
• FTC pts
- Male/ all FTC pts. (%) 1/3 (33.3%) 0/15 (0.0%)
- Female/ all FTC pts. (%) 2/3 (66.7%) 15/15 (100%) 0.021
Age of pts (years)
• Age of all pts 43.86 ± 16.29 48.78 ± 16.69 ns
• Age of PTC pts 44.03 ± 16.18 48.03 ± 16.74 ns
• Age of FTC pts 41.67 ± 21.55 54.93 ± 11.27 ns
Histological subtype of tumors
• Papillary/ all cases (%) 40/43 (93.0%) 190/219 (86.7%)
- Classic 28/40 (70.0%) 143/190 (75.3%)
- Follicular variant 9/40 (22.5%) 34/190 (17.9%)
- Other 3/40 (7.5%) 13/190 (6.8%)
• Follicular/ all cases (%) 3/43 (7.0%) 15/219 (6.9%) ns
• Medullary/ all cases (%) 0/43 (0.0%) 12/219 (5.5%) ns
• Anaplastic/ all cases (%) 0/43 (0.0%) 2/219 (0.9%) ns
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On the other hand, PTC associated with HT showed muta-
tions with less frequency (9/28, 32.1%) than PTC alone (79/
130, 60.7%)(p < 0.005). Within the PTC +HT group classical
papillary morphology was associated with BRAF mutation in
8/18 cases (44.4%), any different morphology presented with
much less mutation frequency (1/10, 10%). None of the cases
with PTC follicular variant morphology appeared to be BRAF
mutant (0/7) (Table 3).
V600E BRAF mutation could be demonstrated in 7/34
(20.6%) PTCs with lymph node metastasis (pN1) while none
of the metastatic PTC +HT cases presented with the mutant-
type BRAF status (0/4, 0%).
Typical oncogenic NRAS mutations of the exons 2, 3 and 4
were also tested in themajority of the cases. A low frequency of
exon 2 codon 12 mutations (2/128, 1.56%) was found, all in
cases with papillary histological type. Other nucleotide variants
or exon 3 and 4 mutations were not be detected. None of the
NRAS variants co-existed with BRAF alteration. We could not
demonstrate any relation of NRAS mutant status to HT etiolo-
gy, papillary morphology or multifocality of the tumor.
Table 3 Correlation of BRAF
V600E mutational status and
histological types in thyroid
carcinoma with and without
coexisting HT
BRAF V600E WT BRAF p value
Histologic type of thyroid cancer
• PTC 88/158 (55.7%) 70/158 (44.3%)
• Other than PTC (FTC, MTC, ATC) 1/27 (3.7%) 26/27 (96.3%) <0.0001
Histologic subtype of PTC
• Classical PTC 70/108 (64.8) 38/108 (35.2%)
• Follicular variant of PTC 15/40 (37.5%) 25/40 (62.5%) 0.0045
• Other variants of PTC 3/10 (30.0%) 7/10 (70.0%)
Presence of HT among PTC pts
• HT+ PTC 9/28 (32.1%) 19/28 (77.9%)
• PTC without HT 79/130 (60.7%) 51/130 (39.3%) <0.005
Subtypes of PTC among HT + PTC pts
• Classical PTC +HT 8/18 (44.4%) 10/18 (55.6%)
• Follicular variant of PTC +HT 0/7 (0.0%) 7/7 (100.0%) 0.0299
• Other variants of PTC +HT 1/10 (10.0%) 9/10 (90.0%)
Table 2 Intra-organ distribution
and pathological stage of thyroid
carcinomas with and without
coexisting HT (MF=multifocal,
UF = unifocal)
HT + TC TC without HT p value
Multifocality
• PTC
- MF/ all PTC cases (%) 16/40 (40.0%) 45/190 (23.7%)
- UF/ all PTC cases (%) 24/40 (60.0%) 145/190 (76.3%) 0.034
• FTC
- MF/ all FTC cases (%) 0/3 (0.0%) 4/15 (26.7%)
- UF/ all FTC cases (%) 3/3 (100.0%) 11/15 (73.3%) ns
pT tumor stage
• PTC 1.33 ± 0.73 1.48 ± 0.76 ns
• FTC 1.33 ± 0.58 1.92 ± 1.19 ns
pN lymph node status
• PTC
- pN1/ all PTC cases 4/11 (34.6%) 34/41 (82.9%)
- pN0/ all PTC cases 7/11 (65.4%) 7/41 (17.0%) 0.002
• FTC
- pN1/ all FTC cases 0/1 (0.0%) 1/1 (100.0%)
- pN0/ all FTC cases 1/1 (100.0%) 0/1 (0.0%) ns
TNM stage
• PTC cases 1.20 ± 0.61 1.33 ± 0.79 ns
• FTC cases 1.00 ± 0 1.69 ± 1.18 ns
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Discussion
Our results - in accordance with previous studies - showed that
thyroid cancer is likely to develop in thyroid glands affected
by Hashimoto’s thyreoiditis and that TC coexisting with HT
presents with characteristic clinico-pathological features. In
association with HTwe found a dominant occurrance of pap-
illary histology, an increase in multifocality and a lower fre-
quency of BRAF mutations.
Our tissue-level studies focussed first on the charasterictics
that could be objectively judged by histology. We found no
difference in either the general morphology or the IHC phe-
notype in PTCs with or without HT that was in agreement
with earlier studies focussing on the panel composed of
CK19, galectin-3 and CD56 [36]. Unlike as referred by Ma
et al. (2014) the use of NGAL and claudin-1 immunostainings
could be abandoned in our study. Interestingly, the HBME-1
antigen revealed the presence of neoplastic growth less sensi-
tively in cases accompanied by HT. Using this limited IHC
panel we were able to reproduce the tissue distribution and
extent of thyroid cancer related to HT as published earlier.
Activation loop mutation (codon 600) of the BRAF gene
leading to the amino acid exchange V600E is the most com-
mon genetic alteration in PTC [31]. It was suggested to pre-
dispose tumor multifocality, extrathyroid spreading, lymph
node metastasis and advanced tumor stage [34]. The analysis
of BRAF V600E sequences and the mutant BRAF protein by
IHC showed a perfect correlation in our present study.
However, we observed significantly lower BRAF mutation
rate (p < 0.005) in PTCs associated with HT compared to
non-HT samples. This was even more prominent in associa-
tion with the follicular variant PTC (0/7 mutant cases). The
mutation frequency occurring in our PTCs with HT cohort
(32.1%) was similar to the one reported by Kim et al. [37].
Lymph node metastasis (pN1) was demonstrated in the
minority of PTC + HT cases which all presented with a
wild-type BRAF status. Metastatic non-HT PTC cases
on the other hand proved to be BRAF-mutant in 7/34
(20.6%). The uncommon occurrance of mutant BRAF
together with the generally higher rate of multifocality would
argue against a carcinogenetic role of mutant BRAF in early
tumor formation induced by HT.
Activating NRAS exon 2, 3 or 4 mutations were described
as relatively rare, but significant in thyroid carcinomas
occuring in approx. 10% in total and associated with adverse
prognosis [38]. NRAS mutations were associated with the
follicular histological type and agressive behaviour in a recent
study performed by next generation sequencing [39].
Although the low number of NRAS mutations generally
deteced in this collective did not allow to draw far
conclusions, based on these limited data a direct
carcinogenetic effect in HT-related thyroid cancer, mostly of
papillary type, seems to be unlikely.
The established coexistance of HT and PTC argues for
parallel pathobiological origins simultaneously involving im-
munological and genetic mechanisms. Subclinical-clinical
forms of HTare generally the result of hyperergic autoimmune
damage affecting the thyroid parenchyma. The enhanced TSH
stimulus together with additional inflammatory citokines act
as potential activators of aberrant cell proliferation throughout
the entire parenchyma corresponding to the classical idea of
„field cancerization^. However, cellular response may be re-
gionally highly different also in regard of suspectibility to
transformation. Our results also clearly demonstrate
multifocality of PTC in the presence of histologically
manifest HT. We definitely could separate more than
one independent tumor site within the same surgical specimen
in 16/40 (40.0%) of our PTC +HT cases. Although this fea-
ture is in agreement with earlier reports, we could not confirm,
that multifocality or metastatic potential is associated with the
mutant BRAF or NRAS genotype in cases with or without HT
etiology.
For this reason, in the absence of MAPK-pathway
mutations alternative genetic or biological factors should
be considered in HT driven multifocal carcinogenesis.
Hypothetically, basic proliferative stimuli manifested in HT
act as tumorigenic in thyroid folliclular epithelial cells. One
major candidate, the RET oncogene activates p21ras, which
also phosphorylates wild-type BRAF, as a potent mitogen-
activated protein phosphorylase. RET/PTC1 and RET/PTC3
fusion gene expression could be deteced by RT-PCR as a
result of common PTC associated chromosomal aberrations
[33]. Wirtschafter and collegues raised the possibility of the
RET gene activation in early forms of HT. They suprisingly
found that the frequency of the mentioned chromosomal ab-
errations in HT was as high as in manifest PTCs [40].
According to this hypothesis, the aberrant expression of the
RET gene in follicular epithelial cells next to the transforming
effect potentially affects the immunogenicity of the same
thyreocytes. Thus, an autoimmune process with features of
HT could be induced as one of the earliest signs of epithelial
transformation.
The PI3K/Akt signaling pathway was implicated in the
maintenance of the balance between pro- and antiapoptotic
signals and in the management of the inflammatory processes
[41]. The PI3K inhibitor PTEN is expressed in normal
thyreocytes and in thyreocytes affected by HT, but suppressed
in transformed epithelial cells of PTC. In samples involved by
both HTand PTC intermediate levels of PTEN expressionwas
reported [37], arguing for an augmented PI3K activity sup-
pressing proapoptotic signals. Further, the p53 homolog p63
protein –among others responsible for a stem cell-like pheno-
type- may also interplay with HT-related thyroid carcinogen-
esis. Alternative splicing results in a smaller, truncated p63
molecule, which is a competitive inhibitor of the tumor
supressor p53. In contrast to the normal epithelium, focal
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p63 expressionwas reported in PTC, especially in the classical
papillary type and in most cases of HT [42].
Chronic immune-activation or autoimmune disease related
carcinogenesis is a well known mechanism generally associated
with slow transformation rates and a generally indolent potential
in e.g. GI tract, liver, skin or lymphoid neoplasias [43]. In line
with these another interesting question iswhyPTCs accompanied
with HT generally show a relatively benign behavior. Marotta
et al. [44] observed that lymphocytic inflitration of HT is protec-
tive against PTCprogression. Similarly,Kim et al. [45] found that
HT-negative papillary TC was associated with an aggressive dis-
ease. These data together with our current results support a mo-
lecular biology different of theMAPkinase pathwaywith limited
progressive capacity in the background of these lesions.
However, special care of patients having syptoms due to their
autoimmune pathology should not be ignored when considering
progressive disease. As also stated by the present study, the path-
ologic stage of the tumor (diameter) proved to be independent of
HT in earlier reports, however, the HT had a „protective^ effect
against extrathyroidmanifestation and nodal involvement [46]. In
our understanding the presence of enlarged lymph nodes great-
ly affect clinical decisions. As HT is frequently compli-
cated by lymphadenomegaly due to persistent immune
activation and lymphatic hyperplasia, regional lymph
nodes are subjects of careful clinical follow-up. Thus,
the regular control of thyroid gland and lymph node
status in HT patients may significantly contribute to the
early detection and surgical treatment of thyroid carcinoma.
The present data, following the earlier reports confirm that
HTcan be regarded as a pre-condition for PTC highlighted by
specific biological features other than BRAF or NRAS acti-
vating mutations. Thanks to the effective long term clinical
care of the underlying disease, PTC can be recognised earlier
which also contributes to the prevention of advanced disease
and metastatic dissemination.
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